Harrow prepares to launch widespread market access for VEVYE

Harrow, Inc. is partnering with three major healthcare technology platforms to support the upcoming commercial launch of its latest FDA-approved product to the U.S. market: VEVYE (cyclosporine ophthalmic solution) 0.1%.

Let’s start with this product.

Originally developed by Novaliq GmbH—and later acquired by Harrow in July 2023—VEVYE (pronounced vee-vye) was approved in May 2023 as the first and only cyclosporine solution indicated to treat the signs and symptoms of dry eye disease (DED, with an efficacy demonstrated at 4 weeks in clinical trials.

The prescription-based, twice-daily (BID)-dosed formulation contains proprietary, preservative- and water-free technology properties, and has a low surface tension and viscosity.

Click here to read through the prescribing information.

Gotcha. Now talk about these three new partners.

They include:

• PhilRx
  • Patient access platform for providing a simplified prior authorization (PA) process via electronic prescriptions
• Apollo Care
  • Comprehensive program for establishing and managing copay program deployment
• PARx Solutions
  • Web-based technology stack for prescribers (free of charge)

How do each of these platforms work?

• PhilRx
  • For patients, click here.
  • For healthcare professionals, click here.
• Apollo Care
  • Core copay program provides services such as program initiation, intelligent data capturing, customizable customer relationship management (CRM) solutions.
  • Advanced copay program offers synchronous copay management, specific blueprint data on payers, and an intelligent prescription intervention that rescues lost revenue from the pharmacy.
• PARx Solutions
  • For prescribers, click here.
    • Prior Authorization Support System (PASS) helps manage the PA process via a web portal, call center of HCPs, and reimbursement specialists to manage care plans.

So why partner?

According to CEO and Chairman Mark L. Baum, the move is based on Harrow’s “360° approach to market access for VEVYE “that’s intended to ensure the eye drop’s target patients are able to access the product.”

“VEVYE represents an important new prescription choice in the U.S. dry eye disease market, and we are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing – with minimum hassle,” he stated.

And most importantly… when is this launching?

Funny you should ask … per Baum: next week.